α-PD-1 treatment reinvigorates CD8 T cells by blocking inhibitory signaling, although one prerequisite for checkpoint therapy responsiveness is an inflamed tumor microenvironment (TME) (37). The gene discussed is CD8A; the disease is neoplasm.